Abeona Therapeutics Inc

Abeona Therapeutics Inc. develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinic...

Read More

ABEO Performance At-A-Glance

RISK EFFICIENCY

-0.69

Abeona Therapeutics Inc's risk efficiency is -0.69, which is poor. By comparison, the S&P500 is -0.43.

Increasing quickly  over the past 4 weeks.

DSCORE

8.98%

Abeona Therapeutics Inc's dScore is 8.98% , which is more volatile than the S&P500 (2.74%).

GROWTH

-66.01%

Abeona Therapeutics Inc has shrunk by -66.01% over the past year.  By comparison, the S&P500 has lost -10.23%.

Portfolios with Abeona Therapeutics Inc